New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTCGIX, CGIX, CGIX, HART, HART, HART, NURO, NURO, NURO, CANF, CANF, CANF, AMBS, AMBS, AMBS, AGEN, AGEN, AGEN, AVXL, AVXL, AVXL, SYN, SYN, SYN, CEMI, CEMI, CEMI, SRNE, SRNE, SRNE, OXBT, OXBT, OXBTOneMedPlace to hold a forum
7th Annual OneMedForum SF 2014 is being held in San Francisco on January 13-15.
News For CGIX;SRNE;CEMI;SYN;AVXL;AGEN;AMBS;CANF;NURO;HART;OXBT From The Last 14 Days
Check below for free stories on CGIX;SRNE;CEMI;SYN;AVXL;AGEN;AMBS;CANF;NURO;HART;OXBT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
07:03 EDTSYNSynthetic Biologics and Fuji Photo Film improve manufacturing of SYN-004 enzyme
Synthetic Biologics (SYN) and Fuji Photo Film (FUJIY) Diosynth Biotechnologies UK Limited confirmed exceptional results from the initial phase of cGMP manufacturing of SYN-004, Synthetic Biologics' proprietary oral beta-lactamase enzyme for the prevention of Clostridium difficile infections. The initial 750-liter cGMP production run on Fujifilm's pAVEway platform yielded an unprecedented 5.5 kilograms of >95% pure SYN-004 active pharmaceutical ingredient drug substance, which will be used to support Synthetic Biologics' planned Phase I and II clinical trials, and continued research and development studies. SYN-004 is believed to be the first and only therapy designed to neutralize intravenous antibiotics in the gut.
August 27, 2014
08:02 EDTCGIXCancer Genetics' proprietary tests added to NIH's genetic testing registry
Subscribe for More Information
August 26, 2014
08:47 EDTSRNESorrento Therapeutics receives funding to advance with WISP1 research
Subscribe for More Information
07:07 EDTSYNSynthetic Biologics on schedule to initiate SYN-004 Phase Ia/Ib trials
Subscribe for More Information
August 25, 2014
08:01 EDTCGIXCancer Genetics announces collaboration to identify, evaluate DLBCL markers
Subscribe for More Information
August 15, 2014
08:13 EDTAMBSAmarantus exercises IP license option for use of MANF in retinal disorders
Subscribe for More Information
August 14, 2014
07:17 EDTCGIXCancer Genetics reports Q2 EPS (50c), consensus (37c)
Subscribe for More Information
06:58 EDTSYNSynthetic Biologics reports Q2 EPS (8c), consensus (7c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use